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Objectives: This study aims to inhibit antiphospholipid syndrome (APS) serum derived IgA
anti-beta-2-glycoprotein I (ab2GPI) binding using Domain I (DI). Methods: Serum from 13
APS patients was tested for IgA ab2GPI and Anti-Domain I. Whole IgA was purified by
peptide M affinity chromatography from positive serum samples. Serum was tested for IgA
ab2GPI binding in the presence and absence of either DI or of two biochemically modified
variants containing either 20 kDa of poly(ethylene glycol) (PEG) or 40 kDa of PEG. Results:
Significant inhibition with DI was possible with average inhibition of 23% (N¼ 13). Further
inhibitions using 20 kDa PEG-DI and 40 kDa PEG-DI variants showed significant inhibition
(p¼ 0.0001) with both the 40 kDa PEG-DI and 20 kDa PEG-DI variants showing increased
inhibition compared with DI alone (p¼ 0.0001 and p¼ 0.001, n¼ 10). Conclusions: Inhibition
of IgA ab2GPI by DI is possible and can be enhanced by biochemical modification in a subset
of patients. Lupus (2019) 0, 1–5.
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Introduction
Antiphospholipid syndrome (APS) is an auto-
immune disorder deﬁned by both laboratory cri-
teria and clinical presentation. Three serological
criteria for APS are included: IgG and IgM anti-
cardiolipin (aCL) and anti-beta-2-glycoprotein I
(ab2GPI) ELISAs, and the lupus anticoagulant
test. Whilst IgG and IgM antiphospholipid antibo-
dies (aPL) are well recognized, the importance of
IgA aPL is still controversial.1,2
Diagnostically IgA aPL has been evaluated in
several studies and found even in patients negative
for the classical diagnostic antibodies2–4 but who
have typical clinical features of APS (seronegative
APS). Part of the controversy regarding IgA aCL
and ab2GPI is due to the variable prevalence
reported in cohorts.5 Some groups found signiﬁcant
clinical associations with thrombosis and APS diag-
nosis,2,6 whilst others did not.7
In vitro studies of IgA aPL have shown patho-
genic potential in a mouse model of APS8 implying
potential pathogenicity in patients in the absence of
IgG and IgM aPL antibodies. Other studies have
suggested this pathogenicity has already been seen
in patients.2,9,10
The standard of treatment for APS patients is
lifelong anticoagulation either by warfarin, heparin
or, more recently, using direct oral anticoagulants
such as rivaroxaban,11 though these have been
shown to have their own risks.12 This has led to a
spate of research into novel therapeutics for
APS.13–15
These novel therapeutics target b2GPI rather
than the clotting cascade, and the majority of
research has been carried out on the IgG subclass.
This study used one of these novel therapeutics
(Domain I) and its modiﬁed forms (PEGylated
DI) to test whether it was possible to disrupt the
binding of patient IgA antibodies to b2GPI immo-
bilized in an ELISA.
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Materials and methods
Patient selection
Thirteen patients were selected from the University
College London Hospital (UCLH) and University
of Istanbul cohorts of patients with APS, with
or without systemic lupus erythematosus (SLE).
Patient sera were tested previously for IgG, IgM
and IgA ab2GPI and Anti-Domain I positivity.2
Data on positivity for aCL and lupus anticoagulant
(LA) were taken from clinic records. Patients with
known IgA positivity were selected for this study.
Preparation of DI and PEG-DI
DI was prepared as previously and PEGylated as
described.13 Brieﬂy: protein was produced bacter-
ially in Escherichia Coli and folded manually
through dilution. Puriﬁcation was by Immobilised
Metal Aﬃnity Chromatography (IMAC), Cation
Exchange Chromatography (CEX) and gel ﬁltra-
tion. PEGylation was carried out using
TheraPEGR targeting disulphide bonds. Two con-
jugates were produced using 20 kDa and 40 kDa
poly(ethylene glycol) (PEG). Expression tag was
removed by FXa cleavage and protein was dialysed
against phosphate-buﬀered saline before quantiﬁ-
cation and storage. Concentrations of PEGylated
conjugates were expressed in terms of mass of DI.
Serum IgG depletion
Serum samples of IgG/IgA ab2GPI positive patients
were depleted using protein G beads. Serum samples
were diluted 1:1 with binding buﬀer (10mM NaPO4,
100mMNaCl, pH7.4) and applied to 100ml of protein
G beads (Sigma) for 1h rotating at room temperature.
Samples were centrifuged (13,000g, 10min, 4C) and
supernatant stored for analysis. Samples were washed
with 500ml of binding buﬀer, centrifuged and bound
IgG was eluted with glycine (0.1M, pH 2.3) rotating
for 1h before centrifugation and neutralization with
10ml of Tris (1M, pH 9.0) per 100ml of glycine.
Serum IgA purification
IgA antibodies were puriﬁed using a peptide M
column (Sigma). Puriﬁcation was as for serum
IgG depletion with the following exception: serum
was diluted 2:1 with 10mM sodium phosphate pH
7.2 and loaded onto a 1ml column.
Direct IgA a2GPI ELISA and inhibition ELISA
Direct ELISAs for IgG and IgA ab2GPI were as
previously described.2 The IgA ab2GPI inhibition
ELISA was carried out as in McDonnell et al.13
with the following alterations: secondary antibody
was an anti-human IgA (Abcam) at a dilution of
1:10,000 and substrate was applied for 20min
before being stopped. DI was used at concentra-
tions ranging from 25 mg/ml to 100 mg/ml, 20 kDa
and 40 kDa PEGylated proteins were used
at 50 mg/ml. Puriﬁed IgA was used between
12.5 mg/ml and 25 mg/ml of IgA, depleted serum
was used at dilutions between 1:12.5 and 1:25
to achieve an optical density (OD) of between 0.4
and 0.8.
Statistical analysis
PRISM and Stata programmes were used to carry
out one-way analysis of variance and non-para-
metric Mann–Whitney t-tests.
Results
Table 1 shows the characteristics of the 13 patients
tested; 11 had venous thrombosis, one had suﬀered
pregnancy morbidity and one patient had both
venous thrombosis and pregnancy morbidity. The
mean IgA aDI and ab2GPI levels were high (42.4
and 68.7 units respectively). Lower levels of IgG
aDI and ab2GPI were seen in these patients (22.6
and 26.1 units respectively). Of the 13 patients,
seven also had SLE and 10 had LA positivity.
Patients were recruited from both the UCLH
cohort of APS patients and a Turkish cohort
from the University of Istanbul.
Table 1 Demographic and disease based details for patients
involved in the study
APS N¼ 13
VT 11
PM 1
VT/PM 1
Gender Four male, nine female
Age 46.2 (19.1)
IgA aDI 38 (32)
IgA ab2GPI 65 (39)
IgG aDI 21 (35)
IgG ab2GPI 25 (34)
LA 10
SLE 7
ab2GPI: anti-beta-2-glycoprotein I; aDI: anti-Domain I; APS: antipho-
spholipid syndrome; LA: lupus anticoagulant; PM: Pregnancy
Morbidity; SLE: systemic lupus erythematosus; VT: Venous
Thrombosis.
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Domain I inhibits patient IgA binding to 2GPI in
serum in a dose-dependent manner
Initially serum samples from patients (N¼ 13) were
screened for inhibition with increasing doses of DI
(0–100 mg/ml). As shown in Figure 1(a) patients
clustered into three groups: no or little inhibition
(cluster 1, n¼ 4), low inhibition (<40% inhibition
at 100 mg/ml, cluster 2, n¼ 5) and high inhibition
(40%inhibition at 100 mg/ml, cluster 3, n¼ 4).
Dose-dependent inhibition for clusters 2 and 3
can be seen in Figure 1(a). Signiﬁcant diﬀerences
were seen between clusters 1 and 2 and clusters 1
and 3 (Figure 1(a)).
Inhibition with 20 kDa PEG-DI and 40 kDa
PEG-DI was carried out at 50 mg/ml. Inhibition
can be seen in Figure 1(b), which includes
10 patients from all three clusters. There was sig-
niﬁcant (p< 0.05) enhancement of inhibition for
both PEGylated forms in comparison with non-
PEGylated DI.
Another interesting result was the diﬀerence in
inhibition for patients with high and low IgG and
IgA. Patients in cluster 1 with low inhibition also
had the lowest levels of both IgG and IgA ab2GPI
(5.08 GBIU and 44.48 ABIU) and aDI (6.02 GDU,
19.92 aDU). Those patients with moderate inhib-
ition in cluster 2 had high IgA (77.08 ABIU, 45.21
ADU) but lower IgG (18.8 GBIU, 9.82 GDU)
whereas those in cluster 3 with the highest inhib-
ition had both high IgG and IgA ab2GPI (64.28
ABIU, 56.63 GBIU) and aDI (53.65 ADU and
52.08 GDU).
To analyse further the high-level inhibition of
IgA ab2GPI binding in serum from patients in clus-
ter 3 we carried out further tests on serum depleted
of IgG and on puriﬁed IgA samples.
IgG depleted serum retains its IgA a2GPI activity,
which is inhibited by non-PEG-DI
Samples from three of the four cluster 3 patients
(patients 1, 2 and 4 in Figure 1(c)) showed signiﬁ-
cant IgG ab2GPI depletion demonstrated by loss of
>80% binding in an IgG ab2GPI ELISA
(Supplementary Material Figure 1 online).
Figure 1 Results of assays to measure inhibition of IgA binding to b2GPI.
(a) The inhibition of IgA ab2GPI in serum from 13 patients separated into three clusters. Cluster 1 had no inhibition, cluster 2 had
moderate inhibition and cluster 3 had the highest inhibition. Significant differences are seen between clusters 1 and 3 at concen-
trations 50 mg/ml DI and between clusters 1 and 2 at 75mg/ml DI. (b) Inhibition by DI and PEG-DI in 10 of these patients
tested with 20 kDa PEG-DI and 40 kDa PEG-DI. Both PEGylated variants show significantly enhanced inhibition. (c) Inhibition
by non-PEGylated DI in IgG depleted serum for all four patients from cluster 3. Inhibition can be seen in all four patients and is
dose-dependent in three cases. (d) Inhibition of purified IgA from three of the patients from cluster 4 (it was not possible to purify
sufficient IgA from serum of patient 2). Inhibition can be seen in all three patients.
ab2GPI: anti-beta-2-glycoprotein I; DI: Domain I; PEG: poly(ethylene glycol)
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IgG-depleted samples retained their IgA ab2GPI
activity suﬃciently to carry out further inhibition
experiments using a dilution that gave an OD
between 0.4 and 0.6 (12.5–25 mg/ml) in the absence
of inhibitor. Doses of DI ranging between 25 mg/ml
and 100 mg/ml showed dose-dependent inhibition of
IgA ab2GPI activity (Figure 1(c)) for patients 1, 2
and 4.
Inhibition of purified IgA a2GPI binding
Puriﬁed IgA was derived from serum of three
patients (1, 3 and 4). Two of these (1 and 4)
showed dose-dependent inhibition between 25 and
100 mg/ml of DI. This can be seen in Figure 1(d).
These results mirrored the eﬀects of non-
PEGylated DI in IgG depleted serum.
Discussion and conclusions
In this study we have shown that it is possible to
inhibit the binding of both puriﬁed and serum IgA
from APS patients from binding to b2GPI.
Interestingly, the inhibitory eﬀect seen with DI
was enhanced by PEGylation. This is an unusual
phenomenon; the majority of PEGylated proteins
lose their natural aﬃnity for ligands. One possible
explanation is that this apparent increase may also
be due to stabilizing the epitope on DI or due to an
increased purity of DI. An alternative theory may
be that DI has aggregated and as such is presenting
multiple epitopes. However, we studied this possi-
bility via a gel-ﬁltration method and also with
native polyacrylamide gel electrophoresis and saw
no aggregation. The potential for aggregation is
also higher in the non-PEGylated protein as
PEGylation has been shown to reduce aggrega-
tion.16,17 These results are in contrast to our previ-
ous research using IgG ab2GPI antibodies where
signiﬁcant inhibitory potential of DI was retained
but not enhanced after PEGylation.13
The strongest inhibition was seen in those
patients with both high IgA aDI/ab2GPI and
high IgG aDI/ab2GPI. To distinguish the eﬀects
of IgG and IgA inhibition we carried out experi-
ments using IgG-depleted serum and puriﬁed IgA.
The results obtained with total serum, IgG-depleted
serum and puriﬁed IgA cannot be compared dir-
ectly in a quantitative way due to the diﬀerences
in sample preparation. However, a qualitative com-
parison shows that inhibition of IgA ab2GPI was
seen in IgG depleted samples and in puriﬁed IgA
for all but one sample. This sample (from patient 3)
was notable because it had particularly high levels
of IgG and IgA ab2GPI binding and because it was
not possible to deplete the IgG ab2GPI. It is pos-
sible that the poor inhibition in this sample was
because of a particularly high level of antibody
binding (both isotypes).
This study utilized patients from two diﬀerent
centres with diﬀerent ethnic backgrounds; however,
the numbers are small. Further studies with larger
cohorts would aid in interpreting these results.
This study shows it is possible to inhibit the
binding of IgA from patients to b2GPI in an
ELISA using DI and PEG-DI and suggests that
the most eﬃcient inhibition is seen in patients
with dual positivity for IgG and IgA antibodies.
It also raises the interesting result that
PEGylation may increase the ability to inhibit
IgA from patients; however, larger studies are
required for this to be conﬁrmed.
Key messages
. Domain I of beta-2-glycoprotein I is capable of
inhibiting IgA antibody binding.
. Biochemical modiﬁcation of Domain I can
increase antibody binding.
. Patients’ serum most inhibited by Domain I con-
tained both high IgA and IgG.
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